作者: Lee M. Greenberger , Deepak Sampath
DOI: 10.1007/978-1-59745-035-5_18
关键词: Cancer research 、 P-glycoprotein 、 Tubulin 、 Paclitaxel 、 Cancer 、 Chemistry 、 Signal transduction 、 Efflux 、 Cancer cell 、 Docetaxel
摘要: Resistance to two taxanes, paclitaxel and docetaxel, is frequently observed in cancer patients limits successful therapy. In experimental systems, resistance docetaxel are mediated by alterations tubulin (the primary site of action taxanes), proteins that interact with microtubules, energy-dependent efflux pumps, apoptotic proteins, signal transduction pathways. Clinical correlations some these exist, but have not been fully elucidated. Strategies overcome or circumvent include inhibition pumps (which largely proven be unsuccessful), the use novel taxanes other chemically distinct classes polymerizing agents do drug (currently clinical trials), regulation pathways would restore sensitivity taxanes. Understanding basis at level likely difficult complex, holds promise providing a therapeutic opportunity specific taxane-resistant cells.